Effect of different doses of atorvastatin on cardiovascular complications in patients with type 2 diabetes

Abstract

Abstract: AIM: To investigate the effect of different doses of atorvastatin on cardiovascular complications in patients with type 2 diabetes. METHODS: 150 cases of type 2 diabetes patients were randomly divided into three groups, control group,conventional lipid-lowering group (atorvastatin 20 mg/d), intensive lipid-lowering group 50 cases (atorvastatin 40 mg/d)(n=50).The conventional therapies in three groups including antiplatelet therapy and hypoglycemic therapy (drugs and/or insulin).All groups were followed up for 3 years, investigate the effect between three groups in cardiovascular complications. RESULTS: Compared with control group,after treatment,the levels of TC and LDL-C were decreased and the levels of HDL-C were increased in conventional lipid-lowering group and intensive lipid-lowering group(P<0.01). After treatment,the TC,LDL-C decreased level and the HDL-C elevated level between conventional lipid-lowering group and intensive lipid-lowering group showed significantly difference(P<0.01). Compared with the control group,the proportion of major cardiovascular complications in 3 years was decreased significantly in the intensive lipid-lowering group and conventional lipid-lowering group(P<0.05). Compared with the conventional lipid-lowering group,the proportion of cardiovascular complications in the intensive lipid-lowering group was decreased significantly (P<0.05).CONCLUSION: Atorvastatin can decrease the cardiovascular complications in patients with type 2 diabetes,the effect of intensive lipid-lowering is better,and has no adverse reaction.

Key words: Atorvastatin, Type 2 diabetes mellitus, Cardiovascular complication

CLC Number:

R587.1

LI Yin, LI Jing-feng, LI Shi-guang, WANG Hou-yang, WANG Cao, CHEN Liang-yu, LU Ming-kui, CAI Da-wei. Effect of different doses of atorvastatin on cardiovascular complications in patients with type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1033-1037.

References

[1] Yan W,Lu J,Weng J,et al.Prenalence of diabetes among men and women in china[J].N Engl J Med,2010,362(12):1090-1101.
[2] 章建萍. 超敏C反应蛋白及血脂检测对糖尿病并发动脉粥样硬化的价值[J].检验医学与临床,2010,7(4):340-341.
[3] Frisinghelli A,Mafrici A.Regression or reduction in progression of atherosclerosis,and avoidance of coronary events,with lovastatin in patients with or at high risk of cardiovascular disease:A Review[J].Clin Drug Investig,2007,27:591-604.
[4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2007年版)[J].中华医学杂志,2008,88(18):1227-1245.
[5] Hermansen K,Mortensen LS,Hermansen ML.Combining insulins with oral antidiabetic agents:effect on hyperglycemic control,markers of cardiovascular risk and disease[J].Vase Health Risk Manag,2008,4(3):561-574.
[6] 汪全汉,王佑民.2型糖尿病合并脂肪肝与血脂紊乱的关系探讨[J].安徽医学,2004,25(1):42-43.
[7] Cleeman JI.Executive summary of the third report of the National Cholesterol of Education Program(NCEP)expert panel on detection,and treatment of high blood cholesterol in adults(Adult Treatment Panel 3)[J]. JAMA, 2001, 285(19): 2486-2497.
[8] 徐向进,潘长玉,田慧,等.糖代谢异常老年人死亡率的分析[J].中华内分泌代谢杂志,2003,19(4):267-270.
[9] 伍华. 糠尿病合并急性心肌梗死和缺血性脑梗塞患者血脂水平的临床观察[J].淮海医药,2004,22(2):127-128.
[10] 吴述兵. 降脂治疗对高血压患者血压的影响[J].中国医学创新,2009,6(34):187-188.
[11] Wenzel P,Daiber A,Oelze M,et al.Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of steptozotocin-induced diabetes mellitus[J].Atherosclerosis,2008,198(1):65-76.
[12] Colhon HM, Betteridge DJ, Durrington PN, et al.Primary prevention of cardiovascular disease with atorvastain in type 2 diabetes in the Collaborstive AtoRvastatin Diabetes Study(CARDS): a multicentre randomized placebocontrolled trail[J]. Lancet, 2004, 364(9435): 685-696.
[13] 孙林,班博,于世鹏,等.老年糖尿病合并冠心病与胰岛素抵抗的关系[J].辽宁实用糠尿病杂志,2004,12(1):45-46.
[14] 何岚,程西峰,李海霞,等.2型糖尿病患者脂代谢状态及影响因素的探讨[J].陕西医学杂志,2004,33(3):265-266.
[15] 邓晓初. 血脂调节治疗对空腹血糖受损并高脂血症74例疗效观察[J].疑难病杂志,2004,3(3):154-155.
[16] 孙珊,吴尚勤.阿托伐他汀非调脂作用的最新进展[J].中国临床药理学与治疗学, 2006,11(2):141-144.